Vera Therapeutics Q2 Loss Narrows to $1.52, Beating Estimates
VERA sits 64% above its 52-week low of $19.25.
Summary
Vera Therapeutics reported a Q2 loss of $1.52 per share, beating the consensus estimate of -$1.56. The company highlighted the recent accelerated FDA approval and commercial launch of TRUTAKNA for IgA nephropathy, with early U.S. market reception described as encouraging. A new Chief Regulatory Officer was announced as part of an executive transition. Looking ahead, final efficacy data from the ORIGIN 3 trial is expected in Q3 2026, with an sBLA submission to follow in Q4 2026, potentially leading to full approval in 2027. The narrower loss and launch progress provide a modest positive signal, though the company continues to burn cash with $499.2M in reserves.
At the time of this announcement, VERA was trading at $31.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $19.25 to $56.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.